Last reviewed · How we verify
NCT03207789: Tcell-Brazil
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
trial in T-cell Lymphoma in 500 participants. Status unknown.
1 June 2017
Quick facts
| Lead sponsor | Grupo de Estudos Multicentricos em Onco-Hematologia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2015 |
| Primary completion | 1 June 2017 |
| Estimated completion | 31 December 2020 |
Conditions studied
- T-cell Lymphoma — all drugs for T-cell Lymphoma →
- NK-Cell Lymphoma — all drugs for NK-Cell Lymphoma →
- T-cell Lymphoma Adults — all drugs for T-cell Lymphoma Adults →
Sponsor
Grupo de Estudos Multicentricos em Onco-Hematologia — full company profile →
Who can join
18 and older, any sex, with T-cell Lymphoma or NK-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The designed study follows up on the previous one by the international T-cell project (Bellei et al,, 2012) and its purpose is to verify whether a prospective collection of data would permit access to more accurate information permitting a better definition of prognosis and investigation of more adequate treatment strategies for these neoplasms. The analysis of patients distributed in all five macro regions of the country and a comparison among them will provide a real picture of the disease in Brazil, limiting the bias probably found in the previous projects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03207789
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for T-cell Lymphoma
Currently open trials in the same condition.
- NCT07388563 — Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · Phase 1 · recruiting
- NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
- NCT06550427 — Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing · recruiting
- NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
- NCT06224049 — Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T · EARLY_PHASE1 · recruiting
Other Grupo de Estudos Multicentricos em Onco-Hematologia trials
Trials by the same sponsor.
- NCT03402295 — Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03207789 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo de Estudos Multicentricos em Onco-Hematologia
- Last refreshed: 5 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03207789.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing